Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.7% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 347,381 shares of the medical research company’s stock after acquiring an additional 12,328 shares during the period. Fifth Third Bancorp owned 0.09% of Thermo Fisher Scientific worth $172,857,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in TMO. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.6% during the fourth quarter. Vanguard Group Inc. now owns 33,249,575 shares of the medical research company’s stock worth $17,297,426,000 after buying an additional 196,864 shares during the period. Capital World Investors lifted its position in Thermo Fisher Scientific by 1.1% during the fourth quarter. Capital World Investors now owns 9,430,120 shares of the medical research company’s stock worth $4,905,812,000 after buying an additional 104,343 shares during the period. Geode Capital Management LLC lifted its position in Thermo Fisher Scientific by 2.6% during the fourth quarter. Geode Capital Management LLC now owns 7,857,385 shares of the medical research company’s stock worth $4,075,540,000 after buying an additional 197,442 shares during the period. Norges Bank purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $3,149,754,000. Finally, Northern Trust Corp lifted its position in Thermo Fisher Scientific by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,910,015 shares of the medical research company’s stock worth $2,034,107,000 after buying an additional 455,004 shares during the period. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently commented on TMO shares. Barclays cut their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Robert W. Baird cut their price objective on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Stifel Nicolaus cut their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Evercore ISI cut their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Finally, Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $605.30.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Stock Up 0.2%

NYSE TMO opened at $415.25 on Thursday. The stock has a fifty day moving average of $417.57 and a 200-day moving average of $493.84. The stock has a market capitalization of $156.76 billion, a P/E ratio of 25.12, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. During the same period last year, the firm earned $5.11 EPS. The business’s revenue for the quarter was up .2% on a year-over-year basis. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.41%. Thermo Fisher Scientific’s dividend payout ratio is currently 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.